- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT03944850
Computerized Anxiety Sensitivity Treatment for Opioid Use Disorders (CAST-O)
3 novembre 2020 aggiornato da: Amanda M. Raines, Southeast Louisiana Veterans Health Care System
Evaluating the Utility of a Brief Computerized Anxiety Sensitivity Intervention for Opioid Use Disorders: A Pilot Investigation
The primary aim of the current project is to test the acceptability and feasibility of a computerized intervention, titled Computerized Anxiety Sensitivity Treatment (CAST), delivered to Veterans seeking treatment for an opioid use disorder.
The second aim of the study is to examine the utility of CAST by gathering data on symptom change.
The final aim of the current study is to test the effects of CAST on rates of attendance and retention in a substance use disorder treatment (SUDT) program.
Panoramica dello studio
Stato
Completato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
The pilot project will examine the effects of a brief, one-session computerized intervention delivered to Veterans seeking treatment for an opioid use disorder.
The opioid epidemic in the United States (US) is having a disproportionate impact on Veterans.
Indeed, Veterans are twice as likely to die from an accidental opioid overdose than members of the general population, even after accounting for gender and age distribution.
Although many individuals with an opioid addiction seek treatment, a large proportion drop out prematurely and/or relapse, highlighting the need to identify modifiable factors that may contribute to this process.
One variable that may be useful in understanding attrition in addiction treatment is anxiety sensitivity (AS).
AS is a well-established psychological risk factor reflecting the tendency to fear anxious arousal due to the belief that this arousal will have harmful physical, mental, and/or social consequences.
AS is elevated in opioid use populations and predicts treatment dropout among opioid users.
Importantly, research suggests that AS is highly malleable.
Despite this, to our knowledge no published research to date has systematically explored the utility of AS reduction protocols among opioid users.
The first aim of the current project is to test the acceptability and feasibility of a brief, one-session Computerized AS Treatment (CAST) delivered to Veterans seeking treatment for an opioid use disorder.
Because this is a pilot project and the study will likely be underpowered to detect treatment effects, we will not emphasize symptom reduction.
Nevertheless, a second aim of the current project is to examine the utility of CAST by gathering data on symptom change.
Finally, a third aim of the current project is to examine the effects of CAST on rates of attendance and retention in a substance use disorder treatment (SUDT) program.
Tipo di studio
Interventistico
Iscrizione (Effettivo)
32
Fase
- Non applicabile
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Luoghi di studio
-
-
Louisiana
-
New Orleans, Louisiana, Stati Uniti, 70119
- Southeast Louisiana Veterans Health Care System
-
-
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
18 anni e precedenti (Adulto, Adulto più anziano)
Accetta volontari sani
No
Sessi ammissibili allo studio
Tutto
Descrizione
Inclusion Criteria:
- Veterans must be diagnosed with an opioid use disorder
Exclusion Criteria:
- Less than 18 years of age
- Actively suicidal
- Actively psychotic
- Uncontrolled bipolar disorder (i.e., not stable on medications for at least one month)
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Computerized Anxiety Sensitivity Treatment
CAST is a newly developed computerized intervention designed to closely model the educational and behavioral techniques that are commonly used in the treatment of anxiety and related conditions.The one time intervention takes approximately 45 minutes to complete.
|
CAST is a newly developed computerized intervention designed to closely model the educational and behavioral techniques that are commonly used in the treatment of anxiety and related conditions.
A psychoeducation component focuses on the nature of anxiety and its effects on the mind and body.
Veterans will be taught that physiological and psychological arousal is not dangerous, although they may have developed a conditioned fear of this arousal.
Interoceptive exposure (IE) exercises will also be introduced to as a way to reduce or eliminate the conditioned fear response.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Intervention Acceptability Questionnaire (IAQ)
Lasso di tempo: One week post-intervention
|
The IAQ is an 11-item self-report questionnaire designed to measure treatment satisfaction.
The IAQ includes nine items assessing acceptability (e.g., Do you think the information provided during the computerized intervention was helpful?
How likely are you to use the information and techniques you learned during the computerized intervention?), which are rated on a 4-point Likert-type scale (0 = no; 1 = somewhat; 2 = moderately; 3 = yes) and two free response items requesting suggestions for improving the treatment.
The IAQ will be administered at post-intervention to allow us to assess treatment acceptability.
|
One week post-intervention
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Alcohol Use Disorders Identification Test (AUDIT)
Lasso di tempo: Baseline
|
The AUDIT is a 10-item self-report questionnaire designed by the World Health Organization to classify individuals with alcohol-related problems.
The AUDIT will be administered at baseline for descriptive purposes.
|
Baseline
|
|
Drug Use Disorders Identification Test (DUDIT)
Lasso di tempo: Baseline
|
The DUDIT is an 11-item self-report questionnaire intended for use with the AUDIT as a way to classify individuals with drug-related problems.
The DUDIT will be administered at baseline for descriptive purposes
|
Baseline
|
|
PTSD Checklist for DSM-5 (PCL-5)
Lasso di tempo: Baseline
|
The PCL-5 is a 20-item self-report questionnaire designed to assess DSM-5 symptoms of PTSD.
The PCL-5 will be administered at baseline for descriptive purposes.
|
Baseline
|
|
Anxiety Sensitivity Index-3 (ASI-3)
Lasso di tempo: Baseline, One week post-intervention, and Four weeks post-intervention
|
The ASI-3 is an 18-item self-report questionnaire designed to measure fear of and concern about the negative effects of anxious arousal.
The ASI-3 will be administered at all timepoints to allow us to assess treatment-related changes in AS.
|
Baseline, One week post-intervention, and Four weeks post-intervention
|
|
Depression Anxiety Stress Scale (DASS)
Lasso di tempo: Baseline, One week post-intervention, and Four weeks post-intervention
|
The DASS is a 21-item self-report questionnaire assessing depression, anxiety, and stress symptoms.
The DASS will be administered at all timepoints to allow us to assess treatment-related changes in depression, anxiety, and stress symptoms.
|
Baseline, One week post-intervention, and Four weeks post-intervention
|
|
Depression Symptom Inventory-Suicide Subscale (DSI-SS)
Lasso di tempo: Baseline, One week post-intervention, and Four weeks post-intervention
|
The DSI-SS is a four-item self-report questionnaire designed to assess suicidal ideation, suicidal plans, control of suicidal thoughts, and suicidal impulses.
The DSI-SS will be administered at all timepoints to allow us to assess treatment-related changes in suicidality.
|
Baseline, One week post-intervention, and Four weeks post-intervention
|
|
Desires for Drug Questionnaire (DDQ)
Lasso di tempo: Baseline, One week post-intervention, and Four weeks post-intervention
|
The DDQ is a 13-item self-report questionnaire designed to measure instant (i.e., present moment) cravings associated with opioid use.
The DDQ will be administered at all timepoints to allow us to assess treatment-related changes in cravings.
|
Baseline, One week post-intervention, and Four weeks post-intervention
|
|
Obsessive Compulsive Drug Use Scale (OCDUS)
Lasso di tempo: Baseline, One week post-intervention, and Four weeks post-intervention
|
The OCDUS is a 12-item self-report questionnaire designed to assess heroin thoughts and interference, intention to use heroin and control of its consumption, and resistance against thoughts and decisions to use heroin.
The OCDUS will be administered at all timepoints to allow us to assess treatment related changes in thoughts and control over thoughts.
|
Baseline, One week post-intervention, and Four weeks post-intervention
|
|
Short Opiate Withdrawal Scale (SOWS)
Lasso di tempo: Baseline, One week post-intervention, and Four weeks post-intervention
|
The SOWS is a 10-item self-report questionnaire designed to assess various symptoms of opiate withdrawal.
The SOWS will be administered at all timepoints to allow us to assess treatment-related changes in withdrawal symptoms.
|
Baseline, One week post-intervention, and Four weeks post-intervention
|
|
Work and Social Adjustment Scale (WSAS)
Lasso di tempo: Baseline, One week post-intervention, and Four weeks post-intervention
|
The WSAS is a 5-item descriptive measure of subjective interference of psychiatric symptoms in various life domains (e.g., work, leisure, and family).
The WSAS will be administered at all timepoints to allow us to assess treatment-related changes in global life domains.
|
Baseline, One week post-intervention, and Four weeks post-intervention
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Investigatori
- Investigatore principale: Amanda M Raines, PhD, Southeast Louisiana Veterans Health Care System
Pubblicazioni e link utili
La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.
Pubblicazioni generali
- Bohnert AS, Valenstein M, Bair MJ, Ganoczy D, McCarthy JF, Ilgen MA, Blow FC. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA. 2011 Apr 6;305(13):1315-21. doi: 10.1001/jama.2011.370.
- Keough ME, Schmidt NB. Refinement of a brief anxiety sensitivity reduction intervention. J Consult Clin Psychol. 2012 Oct;80(5):766-72. doi: 10.1037/a0027961. Epub 2012 Apr 2.
- Schmidt NB, Capron DW, Raines AM, Allan NP. Randomized clinical trial evaluating the efficacy of a brief intervention targeting anxiety sensitivity cognitive concerns. J Consult Clin Psychol. 2014 Dec;82(6):1023-33. doi: 10.1037/a0036651. Epub 2014 May 12.
- Schmidt NB, Eggleston AM, Woolaway-Bickel K, Fitzpatrick KK, Vasey MW, Richey JA. Anxiety Sensitivity Amelioration Training (ASAT): a longitudinal primary prevention program targeting cognitive vulnerability. J Anxiety Disord. 2007;21(3):302-19. doi: 10.1016/j.janxdis.2006.06.002. Epub 2006 Aug 4.
- Hearon BA, Calkins AW, Halperin DM, McHugh RK, Murray HW, Otto MW. Anxiety sensitivity and illicit sedative use among opiate-dependent women and men. Am J Drug Alcohol Abuse. 2011 Jan;37(1):43-7. doi: 10.3109/00952990.2010.535581. Epub 2010 Nov 19. Erratum In: Am J Drug Alcohol Abuse. 2011 Jan;37(1):47.
- Bohnert AS, Ilgen MA, Galea S, McCarthy JF, Blow FC. Accidental poisoning mortality among patients in the Department of Veterans Affairs Health System. Med Care. 2011 Apr;49(4):393-6. doi: 10.1097/MLR.0b013e318202aa27.
- Veilleux JC, Colvin PJ, Anderson J, York C, Heinz AJ. A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid addiction. Clin Psychol Rev. 2010 Mar;30(2):155-66. doi: 10.1016/j.cpr.2009.10.006. Epub 2009 Oct 30.
- Reiss, S. and R. McNally, Expectancy model of fear, in Theoretical Issues in Behavior Therapy, S. Reiss and R. Bootzin, Editors. 1985, Academic Press: San Diego, CA. p. 107-122.
- Lejuez CW, Paulson A, Daughters SB, Bornovalova MA, Zvolensky MJ. The association between heroin use and anxiety sensitivity among inner-city individuals in residential drug use treatment. Behav Res Ther. 2006 May;44(5):667-77. doi: 10.1016/j.brat.2005.04.006. Epub 2005 Jul 5.
- Lejuez CW, Zvolensky MJ, Daughters SB, Bornovalova MA, Paulson A, Tull MT, Ettinger K, Otto MW. Anxiety sensitivity: a unique predictor of dropout among inner-city heroin and crack/cocaine users in residential substance use treatment. Behav Res Ther. 2008 Jul;46(7):811-8. doi: 10.1016/j.brat.2008.03.010. Epub 2008 Mar 28.
- Schmidt NB, Norr AM, Allan NP, Raines AM, Capron DW. A randomized clinical trial targeting anxiety sensitivity for patients with suicidal ideation. J Consult Clin Psychol. 2017 Jun;85(6):596-610. doi: 10.1037/ccp0000195. Epub 2017 Mar 13.
- Barlow, D.H., et al., Behavioral treatment of panic disorder. Behavior Therapy, 1989. 20(2): p. 261-282.
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio (Effettivo)
28 maggio 2019
Completamento primario (Effettivo)
10 gennaio 2020
Completamento dello studio (Effettivo)
31 gennaio 2020
Date di iscrizione allo studio
Primo inviato
6 maggio 2019
Primo inviato che soddisfa i criteri di controllo qualità
7 maggio 2019
Primo Inserito (Effettivo)
10 maggio 2019
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
5 novembre 2020
Ultimo aggiornamento inviato che soddisfa i criteri QC
3 novembre 2020
Ultimo verificato
1 novembre 2020
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 365
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
NO
Descrizione del piano IPD
Data sets underlying this project will not be shared outside the VA, except as required under the Freedom of Information Act (FOIA), for a number of reasons.
First, data will be used by the research team to answer additional research questions.
Further, veterans may be hesitant to participate in research in which the data will be shared outside the VA and this may act as a barrier to participation and/or benefit from treatment.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
No
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
No
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .